HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
HCW Biologics Inc. (HCWB)
Company Research
Source: GlobeNewswire
MIRAMAR, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and diseases, announced today the data presented for their tetra-valent, second-generation T-Cell Engager (“TCE”) Program based on their novel TRBC platform technology, at the SITC 40th Annual Meeting, taking place from November 5 to 9, 2025 in National Harbor, Maryland. HCW Biologics debuted the results from its preclinical study of HCW11-018b, the Company’s lead T-cell engager product candidate, that highlights the uniqueness and advantages of its second-generation TCE program compared with the first-generation TCE products. Its unique features include: Broad coverage for human solid tumor indications by targeting tissue factor, with high potency and precision, shown in xenograf
Show less
Read more
Impact Snapshot
Event Time:
HCWB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HCWB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HCWB alerts
High impacting HCW Biologics Inc. news events
Weekly update
A roundup of the hottest topics
HCWB
News
- HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq RulesGlobeNewswire
- HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune DiseaseGlobeNewswire
- HCW Biologics GAAP EPS of -$2.02, revenue of $15.60M [Seeking Alpha]Seeking Alpha
- HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial ResultsGlobeNewswire
- HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of CancerGlobeNewswire
HCWB
Sec Filings
- 11/20/25 - Form 8-K
- 11/19/25 - Form 8-K
- 11/18/25 - Form 8-K
- HCWB's page on the SEC website